by Entheon Biomedical | Nov 26, 2019 | Industry News, Uncategorized
The US Food and Drug Administration (FDA) has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD). This new FDA...
by Entheon Biomedical | Nov 12, 2019 | Industry News, Uncategorized
Time for a change of mind? Drugs like magic mushrooms and ecstasy are widely banned. But brain-altering drugs are showing promise in treating intractable mental health problems. Last year, a treatment derived from party drug ketamine became the first new type of...
Recent Comments